Wellington Management Group LLP Purchases 5,371 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Wellington Management Group LLP boosted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYNFree Report) by 4.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 115,935 shares of the company’s stock after buying an additional 5,371 shares during the quarter. Wellington Management Group LLP owned approximately 0.19% of Dyne Therapeutics worth $1,039,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. raised its stake in shares of Dyne Therapeutics by 36.9% during the third quarter. American Century Companies Inc. now owns 27,407 shares of the company’s stock valued at $246,000 after acquiring an additional 7,389 shares during the last quarter. Deutsche Bank AG raised its position in Dyne Therapeutics by 23.2% during the 3rd quarter. Deutsche Bank AG now owns 21,423 shares of the company’s stock valued at $192,000 after purchasing an additional 4,031 shares during the last quarter. Walleye Trading LLC purchased a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $218,000. Walleye Capital LLC bought a new stake in shares of Dyne Therapeutics in the 3rd quarter worth approximately $2,511,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Dyne Therapeutics by 45.4% during the third quarter. The Manufacturers Life Insurance Company now owns 25,129 shares of the company’s stock valued at $225,000 after buying an additional 7,848 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In related news, insider Wildon Farwell sold 1,585 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $25.70, for a total value of $40,734.50. Following the completion of the transaction, the insider now directly owns 151,590 shares in the company, valued at approximately $3,895,863. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Wildon Farwell sold 1,585 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the sale, the insider now directly owns 151,590 shares of the company’s stock, valued at $3,895,863. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dirk Kersten bought 1,714,285 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was acquired at an average cost of $17.50 per share, with a total value of $29,999,987.50. Following the transaction, the director now owns 6,416,793 shares in the company, valued at approximately $112,293,877.50. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 2,165,394 shares of company stock valued at $49,837,369. 32.89% of the stock is owned by insiders.

Dyne Therapeutics Stock Down 0.4 %

Shares of DYN opened at $28.39 on Friday. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $30.27. The stock has a market cap of $2.33 billion, a P/E ratio of -7.21 and a beta of 0.95. The business’s 50 day moving average price is $24.01 and its 200-day moving average price is $15.36.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last released its earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.23 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DYN. Piper Sandler raised their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, March 6th. Chardan Capital raised their price objective on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, March 8th. Oppenheimer reiterated an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a report on Tuesday. Finally, StockNews.com upgraded Dyne Therapeutics to a “sell” rating in a research note on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.43.

Read Our Latest Stock Analysis on DYN

Dyne Therapeutics Company Profile

(Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Featured Stories

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYNFree Report).

Institutional Ownership by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.